评价Galcanezumab治疗的发作性或慢性偏头痛成年患者的心血管结局:来自三个3期、随机、双盲、安慰剂对照的EVOLVE‐1、EVOLVE‐2和gain研究的数据

Headache: The Journal of Head and Face Pain Pub Date : 2019-11-13 DOI:10.1111/head.13684

T. Oakes, R. Kovacs, Noah L Rosen, E. Doty, P. Kemmer, S. Aurora, A. Camporeale

{"title":"评价Galcanezumab治疗的发作性或慢性偏头痛成年患者的心血管结局:来自三个3期、随机、双盲、安慰剂对照的EVOLVE‐1、EVOLVE‐2和gain研究的数据","authors":"T. Oakes, R. Kovacs, Noah L Rosen, E. Doty, P. Kemmer, S. Aurora, A. Camporeale","doi":"10.1111/head.13684","DOIUrl":null,"url":null,"abstract":"Blood pressure (BP), pulse, electrocardiogram (ECG), and clinical cardiovascular (CV) outcomes in patients with episodic or chronic migraine treated for up to 6 months with galcanezumab compared to placebo were evaluated.","PeriodicalId":12845,"journal":{"name":"Headache: The Journal of Head and Face Pain","volume":"29 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"26","resultStr":"{\"title\":\"Evaluation of Cardiovascular Outcomes in Adult Patients With Episodic or Chronic Migraine Treated With Galcanezumab: Data From Three Phase 3, Randomized, Double‐Blind, Placebo‐Controlled EVOLVE‐1, EVOLVE‐2, and REGAIN Studies\",\"authors\":\"T. Oakes, R. Kovacs, Noah L Rosen, E. Doty, P. Kemmer, S. Aurora, A. Camporeale\",\"doi\":\"10.1111/head.13684\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Blood pressure (BP), pulse, electrocardiogram (ECG), and clinical cardiovascular (CV) outcomes in patients with episodic or chronic migraine treated for up to 6 months with galcanezumab compared to placebo were evaluated.\",\"PeriodicalId\":12845,\"journal\":{\"name\":\"Headache: The Journal of Head and Face Pain\",\"volume\":\"29 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-11-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"26\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Headache: The Journal of Head and Face Pain\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1111/head.13684\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Headache: The Journal of Head and Face Pain","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/head.13684","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 26

摘要

与安慰剂相比，用galcanezumab治疗长达6个月的发作性或慢性偏头痛患者的血压(BP)、脉搏、心电图(ECG)和临床心血管(CV)结果进行了评估。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Evaluation of Cardiovascular Outcomes in Adult Patients With Episodic or Chronic Migraine Treated With Galcanezumab: Data From Three Phase 3, Randomized, Double‐Blind, Placebo‐Controlled EVOLVE‐1, EVOLVE‐2, and REGAIN Studies

Blood pressure (BP), pulse, electrocardiogram (ECG), and clinical cardiovascular (CV) outcomes in patients with episodic or chronic migraine treated for up to 6 months with galcanezumab compared to placebo were evaluated.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Headache: The Journal of Head and Face Pain

自引率

0.00%

发文量